Research programme: mRNA therapeutics - Alexion/Moderna Therapeutics

Drug Profile

Research programme: mRNA therapeutics - Alexion/Moderna Therapeutics

Alternative Names: ALXN 1540

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Alexion Pharmaceuticals; Moderna Therapeutics
  • Class RNA
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Liver disorders

Most Recent Events

  • 16 Mar 2017 Alexion in-licenses lipid nanoparticle (LNP) technology from Arbutus
  • 12 Jul 2016 Preclinical trials in Liver disorders in USA (unspecified route) before July 2016
  • 12 May 2015 Elpidera collaborates with Alexion Pharmaceuticals to develop mRNA-based medicines for rare diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top